In licensing Maze’s oral contender, the group has made another bet against gene therapies.
2023 begins with FDA decisions for Eisai’s Alzheimer’s project and Pfizer’s zavegepant, with an adcom for Cidara’s rezafungin.
The group looks like the gene therapy contender to beat, but that is not saying much.
Amicus and Astrazeneca have notable approaching Pdufa decisions, while a panel for GSK’s daprodustat could change the course of a controversial drug class.
Pdufa decisions also beckon for Amicus, Acadia and Bluebird.